Acrivon Therapeutics, Inc. (ACRV) stock
Close on Nov 11, 2026Market cap $67.28MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $67.28M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.78
- Dividend yield
- –
- Free cash flow yield
- -95.33%
Fundamentals
- Net income
- -$74.23M
- EPS, diluted
- -$1.88
- Free cash flow
- -$64.14M
- Book value per share
- $2.07
- Diluted shares
- 42M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $1.57
- Open
- $1.57
- Day's range
- $1.55 – $1.65
- Volume
- 218,788
- Average volume (20 days)
- 179,222
- Beta (5 years)
- 1.55
- 52-week range
- $1.27 – $3.56
- RSI (14 days)
- 38.6
- Volatility (1 year)
- 86.9%
- Relative volume
- 0.66×
- WACC
- 12.6%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACRV | S&P 500 | Difference | ACRV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.8% | -2.4% | −15.4 pts | ||
| 3 months | -9.2% | -1.2% | −8.1 pts | ||
| Year to date | -34.9% | +12.3% | −47.1 pts | ||
| 1 year | -24.2% | +12.4% | −36.6 pts | ||
| 3 years | -64.1% | +78.8% | −142.9 pts | -28.9% | +21.4% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Acrivon Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Results
- Results
- Results
- Results
About Acrivon Therapeutics
Pharmaceutical Preparations
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology medicines. The company utilizes its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics (AP3) platform to quantify drug-regulated pathway activity levels inside intact tumor cells in an unbiased manner. Its core pipeline includes ACR-368 (prexasertib), a targeted CHK1 and CHK2 inhibitor undergoing Phase 2b clinical trials for indications such as endometrial cancer, and ACR-2316, a selective dual WEE1/PKMYT1 inhibitor in Phase 1 evaluation. In addition, Acrivon advances ACR-6840 targeting CDK11. The company uses drug-tailored OncoSignature companion diagnostic tests to match targeted therapies with specific patients likely to respond.
Company profile, executives and historyAcrivon Therapeutics stock: common questions
What is Acrivon Therapeutics's stock price?
ACRV closed at $1.57 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.27 and $3.56.
What is Acrivon Therapeutics's market cap?
Acrivon Therapeutics was worth $67.28M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ACRV's P/E ratio?
Acrivon Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.88), so it has no meaningful P/E ratio.
Does Acrivon Therapeutics pay a dividend?
No. Acrivon Therapeutics has not paid a cash dividend over the last twelve months.
When does Acrivon Therapeutics report earnings next?
Acrivon Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ACRV stock performed over the past year?
Including dividends, ACRV returned -24.2% over the past year, against +12.4% for the S&P 500.
How many ACRV shares are sold short?
2M shares were sold short at the latest FINRA report, 10.79% of the float, or 11.4 days of average trading volume.
Who are Acrivon Therapeutics's competitors?
Companies most similar to Acrivon Therapeutics by business, industry and size include APRE, TNGX, PRLD, ALLR, AKTS.
See a number that looks wrong?